Curanex Pharmaceuticals Inc Common Stock
CURXCuranex Pharmaceuticals is a developmental stage pharmaceutical company focused on the discovery, development, and commercialization of innovative botanical drugs for inflammatory diseases.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Curanex Pharmaceuticals is a developmental stage pharmaceutical company focused on the discovery, development, and commercialization of innovative botanical drugs for inflammatory diseases. The company leverages natural substances and traditional Chinese medicine history to address unmet medical needs in autoimmune, metabolic, and viral conditions. Its core value proposition lies in a multi-target mechanism of action that aims to provide comprehensive treatment effects with potentially favorable tolerability compared to single-target chemical compounds.
An early-stage entrant in the niche botanical drug space, seeking to become one of the few companies to achieve FDA approval for complex plant-derived therapies.
Questions, answered.
- What is Curanex Pharmaceuticals Inc Common Stock's market cap?
- Curanex Pharmaceuticals Inc Common Stock (CURX) has a market capitalization of $6.0M and trades on NASDAQ.
- Who are Curanex Pharmaceuticals Inc Common Stock's competitors?
- Curanex Pharmaceuticals Inc Common Stock's key competitors include AbbVie, Pfizer, Sanofi, and others. These companies compete in similar markets and product categories.
- Who does Curanex Pharmaceuticals Inc Common Stock partner with?
- Curanex Pharmaceuticals Inc Common Stock's notable partners include Dominari Securities, LLC, Rutgers University, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, and others.
- Where is Curanex Pharmaceuticals Inc Common Stock headquartered?
- Curanex Pharmaceuticals Inc Common Stock is headquartered in United States of America. It has been publicly traded since 2025.